Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
r-Sak for acute ischemic stroke (Phase II, China)
CTR20244138Phase 2Active
- Sponsor
- Kanion Yujin Pharmaceutical
- Start
- Nov 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of staphylokinase in ischemic stroke, sponsored by Kanion Yujin Pharmaceutical. Started Nov 2024; status: active.
02
Drugs
staphylokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20244138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244138.